(34) – Late Cytomegalovirus (CMV) Infections in Heart Transplantation (HT)

2.48-68.39, p= 0.024). A significant decrease in mean anti-CMV titers (baseline vs. day 30) was observed in both groups (CMV disease: 20419±14483 vs. 14235±11963, p= 0.044; no-CMV disease: 23232±2134 vs. 18247±1747, p< 0.001). There were no significative differences in mean specific anti-CMV titers between both groups in the analyzed study points. Conclusion: In conclusion, CMV-seropositive heart transplant recipients at risk for CMV disease can be identified based on readily assessable immunological biomarkers. Preventive strategies may be selectively targeted toward these patients.